High importance
Sep 17, 2026
To evaluate the efficacy of engasertib 40 mg once daily in reducing the frequency of epistaxis in patients with moderate to severe Hereditary Hemorrhagic Telangiectasia (HHT) over a 28-week period.
A randomized, double-blind, placebo-controlled trial involving participants diagnosed with moderate to severe HHT, where one group receives engasertib and the other receives a placebo. The frequency of epistaxis will be the primary endpoint observed during the treatment duration.
Data regarding the reduction in epistaxis frequency, safety profile, and any adverse events will be analyzed to determine the efficacy of engasertib. Preliminary findings may indicate a measurable impact compared to placebo, but detailed statistical results are pending.
The trial may be limited by its short duration, sample size, and the specificity of participant eligibility based on HHT severity. Additionally, findings might not be generalizable to all HHT patients due to the population's heterogeneity in genetic mutations and clinical presentations.
Reducing the frequency of epistaxis in HHT patients markedly improves quality of life and addresses a significant symptom of the disease. This trial could pave the way for targeted therapies in managing HHT, potentially offering a new treatment paradigm that goes beyond current management strategies.
The primary objective of this trial is to assess the efficacy of engasertib 40 mg once daily (QD) in reducing the frequency of epistaxis compared to placebo QD during 28 weeks of double-blind treatment in participants with moderate to severe HHT.